Table 1 Current Combination Immunotherapy Trials Including HNSCC Patients
Targets | Treatments | Phase | Clinical Trial ID | Patient Eligibility | Status |
|---|---|---|---|---|---|
Costimulatory/Checkpoint Combinations | |||||
 CD137 (4-1BB)  PD-L1 | PF-05082566 + Avelumab | Ib/II | NCT02554812 | Advanced/metastatic solid tumors | Recruiting |
 CD137 (4-1BB)  PD-1 | PF-05082566 + Pembrolizumab | I | NCT02179918 | Advanced/metastatic solid tumors | Recruiting |
 OX40  PD-L1 | MEDI6383 +/−Durvalumab | I | NCT02221960 | Recurrent or metastatic solid tumors | Recruiting |
 OX40  CTLA-4  PD-L1 | MEDI6469 Alone, + Tremelimumab, or + Durvalumab | Ib/II | NCT02205333 | Advanced solid tumors | Ongoing, not recruiting |
 CD27  PD-L1 | Varlilumab + Atezolizumab | I/II | NCT02543645 | Advanced cancers including HNSCC | Recruiting |
 CD27  PD-1 | Varlilumab + Nivolumab | I/II | NCT02335918 | Advanced solid tumors | Recruiting |
Checkpoint/Checkpoint Combinations | |||||
 CTLA-4  B7-H3 | Ipilimumab + MGA271 | I | NCT02381314 | Advanced/metastatic B7-H3+ HNSCC, melanoma, or NSCLC | Recruiting |
 CTLA-4  PD-L1 | Tremelimumab + Durvalumab | III | NCT02551159 | HNSCC with no prior chemotherapy | Recruiting |
 CTLA-4  PD-L1 | Tremelimumab + Durvalumab | I | NCT02262741 | Recurrent or metastatic HNSCC | Recruiting |
 CTLA-4  PD-L1 | Tremelimumab + Durvalumab (monotherapy or combination) | II | NCT02319044 | Recurrent or metastatic HNSCC | Ongoing, not recruiting |
 CTLA-4  PD-L1  Vaccine | Tremelimumab + Durvalumab + PolyICLC | I/II | NCT02643303 | Advanced solid tumors including HPV- HNSCC or HPV+ HNSCC after prior treatment failure | Not yet recruiting |
 PD-L1  CTLA-4 | Durvalumab +/−Tremelimumab | III | NCT02369874 | Recurrent or metastatic HNSCC | Recruiting |
 PD-1  B7-H3 | Pembrolizumab + MGA271 | I | NCT02475213 | B7-H3+ advanced HNSCC | Recruiting |
 PD-L1  HPV E7 | Durvalumab + ADXS 11–001 | I/II | NCT02291055 | Recurrent or metastatic HPV-associated HNSCC | Ongoing, not recruiting |
 LAG-3  PD-1 | BMS-986016 +/− Nivolumab | I | NCT01968109 | Advanced solid tumors | Recruiting |
 LAG-3  PD-1 | LAG525 +/− PDR001 | I/II | NCT02460224 | Advanced solid tumors | Recruiting |
 TIM-3  PD-1 | MBG453 +/−PDR001 | I/II | NCT02608268 | Advanced solid malignancies | Recruiting |
Cetuximab Combinations | |||||
 CD137 (4-1BB) | Urelumab + Cetuximab | Ib | NCT02110082 | Advanced/metastatic HNSCC or CRC | Ongoing, not recruiting |
 CTLA-4 | Iplimumab + Cetuximab + IMRT | Ib | NCT01860430, NCT01935921 | Stage III-IVB HNSCC p16- or intermediate-risk p16+ | Recruiting |
 TLR8 | Cetuximab + SOC Chemo (CDDP + 5-FU) +/− VTX-2337 | II | NCT01836029 | Recurrent or metastatic HNSCC | Ongoing, not recruiting |
 TLR8 | Cetuximab + VTX-2337 window of opportunity before surgery | Ib | NCT02124850 | Stage II-IVA resectable HNSCC | Recruiting |